Our May 2026 update covered Olympus's claimed 96% completion of its FDA quality commitments and the still-active import alert on 58 device models. Since then, the central new development is not a court ruling or an MDL motion. It is a recall — of the device hospitals use to clean Olympus duodenoscopes. That widens the compliance picture in a way patients with potential cases should understand.
The April 2026 OER-Pro Reprocessor Recall
On April 8, 2026, the FDA posted a nationwide recall covering 3,354 units of the Olympus OER-Pro automated endoscope reprocessor (model N3058140). The reason: two related accessory components (the MAJ-1443 and MAJ-1444) are no longer compatible with the OER-Pro and OER-Elite reprocessors, and the resulting incompatibility, in the FDA's words, "could affect patient safety." The agency rated the action a medium-severity recall.
The OER-Pro is not a duodenoscope. It is the automated washing and disinfection machine that many U.S. hospitals use to reprocess flexible endoscopes — including Olympus duodenoscopes — between patients. Failures in automated reprocessing have been a documented theme in scope infection cases for more than a decade, and the FDA's reprocessing guidance specifically calls out the chain of custody from procedure to washer to next patient.
For prospective plaintiffs, the recall does two things. First, it extends the contamination story beyond the scope itself to the equipment used to clean the scope — an additional thread of regulatory documentation that may be cited in hospital reprocessing negligence claims as well as product liability claims against the manufacturer. Second, it confirms that the compliance issues identified in the June 2025 import alert are not narrowing — they are widening.
Two Earlier 2026 Recalls in the Same Pattern
The April reprocessor recall is the third Olympus action of 2026 to reach the FDA's recall database. Two earlier actions are worth reading together with it.
January 16, 2026 — High Flow Insufflation Units (UHI, UHI-2, UHI-3). Olympus sent customers a removal letter recommending immediate quarantine after determining that a software algorithm in these units could cause over-pressure events during laparoscopic procedures. Because no software correction was available for the affected models, Olympus pulled the devices from the market entirely. The FDA classified the recall as Class I — its most serious category — and ultimately linked the issue to 10 injuries and one death. Over-insufflation can cause air embolism, cardiac arrhythmias (including asystole), pneumothorax, hypoxia, and other serious harms.
January 22, 2026 — Endoscope needle recall expansion. Olympus expanded an earlier recall of disposable endoscope needles. The expansion broadened the scope of affected lots and reinforced the pattern the FDA flagged in its 2025 import alert: quality system findings at the Aizu, Japan facility had downstream effects across multiple product lines, not only duodenoscopes.
Taken together, the three 2026 actions reach across three different categories of device — reprocessing equipment, insufflation hardware, and disposable accessories — and add another year of regulatory record to the case file.
Import Alert: Still in Place, No FDA Lift
The June 24, 2025 import alert blocking 58 Olympus device models from the company's Aizu, Japan facility remains active as of this writing. The FDA has not announced verification of Olympus's claimed 96% completion of corrective actions and has not posted a lift. Hospitals that already have the affected scopes can keep using them under the FDA's existing labeling guidance, but new units cannot enter the United States.
That status is meaningful in two ways. The import alert is a formal regulatory finding that documents quality system violations — the kind of record that becomes evidence in product liability cases. And the fact that it has not been lifted, more than eleven months after issuance, suggests the FDA is not yet satisfied with Olympus's corrective work.
U.S. Cases: Still No MDL
The structural picture in U.S. courts is unchanged from our April and May updates. The Judicial Panel on Multidistrict Litigation has not consolidated Olympus endoscope cases into an MDL, and no JPML hearing in the spring 2026 sessions has taken up the question. Plaintiffs continue to file individual product liability actions in state and federal courts.
Whether that holds for the rest of 2026 depends on filing volume. If the 2026 wave of recalls drives a second surge of cases through federal courts, an MDL motion becomes more likely; if filings continue at the current per-case pace, courts will keep handling them individually. Either path is workable for patients with a strong case — what changes is the timeline and the discovery dynamics.
What This Means for Patients with Potential Cases
The practical point we've made each month this year remains the most important one: your filing window is set by your state's statute of limitations, and it does not pause while you wait to see whether an MDL forms or whether the FDA lifts the import alert. If you developed a serious infection after an Olympus scope procedure, the calendar is the variable you control least and the variable that controls your case the most.
Some states use a "discovery rule" that can extend the window for patients who only recently connected a past infection back to a contaminated scope. That analysis is fact-specific and timing-sensitive, and we evaluate it case by case in a free review before you decide whether to move forward.
What to Watch the Rest of Summer 2026
- FDA verification — or further enforcement. The agency has not confirmed Olympus's claimed 96% corrective-action completion. A formal verification (or, conversely, a new Form 483 or warning letter) would be a meaningful shift.
- Possible MDL motion. If federal case counts continue to rise, expect counsel for the larger plaintiff firms to weigh a centralization motion to the JPML. Once filed, a decision typically follows in months, not years.
- Additional 2026 recalls. The reprocessor and insufflation actions show that Olympus's compliance work is producing more recalls, not fewer, as the company moves through its FDA commitments. Each new action becomes part of the regulatory record.
- Health Canada follow-through. The April 2026 Quebec class action filing by Siskinds LLP is still in its authorization phase. Documents produced there may eventually surface in U.S. discovery.
- State outbreak investigations. State health departments occasionally publish their own investigations of hospital-acquired infections. Those reports can become evidence in private cases.
If You Were Affected
The pattern we keep seeing is the same: a patient had a colonoscopy, ERCP, or other endoscopic procedure, was discharged, and within days or weeks developed a serious infection that nobody connected back to the scope at the time. Often the connection only becomes clear months or years later — after a hospital outbreak is reported, after a news story prompts the patient to ask questions, or after a friend or family member notices a pattern.
We represent patients nationwide, regardless of where the procedure happened. A free case review takes about 15 minutes by phone, and we evaluate the medical timeline, the device involved, and your state's filing deadlines before you decide whether to move forward.
- See if your situation fits the case profile with our 3-part qualification test.
- Learn how to identify which scope was used in your procedure: Did Your Hospital Use Olympus Scopes?
- Review the superbug infection symptoms guide for warning signs to watch for.
- Read the underlying regulatory backdrop: What the June 2025 FDA Import Alert Means for You.
Free case review. No Fees Unless We Recover Money for You.
Sources
- U.S. Food & Drug Administration — "Early Alert: Insufflation Unit Issue, Olympus." fda.gov
- U.S. Food & Drug Administration — "Insufflation Unit Recall: Olympus Removes High Flow Insufflation Units" (January 2026, Class I). fda.gov
- FierceBiotech — "FDA links Olympus laparoscopic insufflation hardware recall to 10 injuries, one death." fiercebiotech.com
- American Hospital Association — "Olympus expands recall of endoscope needles" (January 22, 2026). aha.org
- U.S. Food & Drug Administration — Medical Device Recalls Database, Olympus OER-Pro / OER-Elite reprocessor (April 8, 2026; 3,354 units; MAJ-1443 / MAJ-1444 incompatibility). fda.gov
- U.S. Food & Drug Administration — "Import Alerts for Certain Olympus Medical Devices Manufactured in Japan: Letter to Health Care Providers." fda.gov
- U.S. FDA MAUDE Adverse Event Database — reports involving Olympus duodenoscope models. accessdata.fda.gov
- Judicial Panel on Multidistrict Litigation — pending MDL list and hearing sessions. jpml.uscourts.gov
- Olympus Medical — "Olympus High Flow Insufflation Unit Customer Letter" (January 2026, US). medical.olympusamerica.com
Think You May Have a Case?
The 3-part qualification test takes 2 minutes. If it fits your situation, a free case review is the next step. No Fees Unless We Recover Money for You.